STOCK TITAN

Monogram Technologies Named Orthopedic Joint Replacement Company of the Year 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Monogram Technologies (NASDAQ:MGRM) has been named Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook. The award recognizes the company's stellar reputation and trust among customers and industry peers, particularly highlighting their mBôs TKA Precision Robotic Surgical System. The selection process involved an exhaustive evaluation by C-level executives, industry thought leaders, and the editorial board, following numerous nominations from Medical Tech Outlook's subscribers.

Monogram Technologies (NASDAQ:MGRM) è stata nominata Azienda dell'Anno 2024 per la Sostituzione Articolare Ortopedica da Medical Tech Outlook. Questo premio riconosce l'eccellente reputazione e fiducia dell'azienda tra i clienti e i colleghi del settore, evidenziando in particolare il loro Sistema Chirurgico Robotico di Precisione mBôs TKA. Il processo di selezione ha coinvolto una valutazione approfondita da parte di dirigenti di livello C, leader di pensiero del settore e del comitato editoriale, dopo numerose nomination da parte degli abbonati di Medical Tech Outlook.

Monogram Technologies (NASDAQ:MGRM) ha sido nombrada Empresa del Año 2024 en Reemplazo de Articulaciones Ortopédicas por Medical Tech Outlook. Este premio reconoce la destacada reputación y confianza de la empresa entre sus clientes y colegas de la industria, destacando en particular su Sistema Quirúrgico Robótico de Precisión mBôs TKA. El proceso de selección incluyó una evaluación exhaustiva por parte de ejecutivos de nivel C, líderes de opinión del sector y el consejo editorial, tras numerosas nominaciones de los suscriptores de Medical Tech Outlook.

모노그램 테크놀로지스 (NASDAQ:MGRM)는 Medical Tech Outlook에 의해 2024년 정형외과 관절 교체 회사로 선정되었습니다. 이 상은 고객과 업계 동료들 사이에서 회사의 뛰어난 명성과 신뢰를 인정하며, 특히 그들의 mBôs TKA 정밀 로봇 수술 시스템을 강조합니다. 선정 과정은 C급 경영진, 업계 사상 리더 및 편집위원회에 의한 철저한 평가를 포함하였으며, Medical Tech Outlook 구독자들로부터 많은 추천이 있었습니다.

Monogram Technologies (NASDAQ:MGRM) a été nommé Société de l'Année 2024 pour le Remplacement Articulaire Orthopédique par Medical Tech Outlook. Ce prix reconnait la réputation et la confiance impressionnantes de l'entreprise parmi ses clients et ses pairs du secteur, mettant particulièrement en avant leur Système Chirurgical Robotique de Précision mBôs TKA. Le processus de sélection a impliqué une évaluation exhaustive par des cadres supérieurs, des leaders d'opinion dans l'industrie et le conseil de rédaction, suite à de nombreuses nominations des abonnés de Medical Tech Outlook.

Monogram Technologies (NASDAQ:MGRM) wurde von Medical Tech Outlook zum Unternehmen des Jahres 2024 für Orthopädische Gelenkersatzoperationen ernannt. Diese Auszeichnung würdigt den hervorragenden Ruf und das Vertrauen des Unternehmens unter Kunden und Branchenkollegen, insbesondere hervorzuheben ist ihr mBôs TKA Präzisions-Roboterchirurgisches System. Der Auswahlprozess umfasste eine umfassende Bewertung durch Führungskräfte der oberen Managementebene, Branchenexperten und das Redaktionsteam, nach zahlreichen Nominierungen von Abonnenten von Medical Tech Outlook.

Positive
  • Recognition as Orthopedic Joint Replacement Company of the Year 2024 enhances company credibility
  • Strong industry validation of mBôs TKA System technology
Negative
  • None.

Award from Medical Tech Outlook Highlights Monogram's mBôs TKA System

AUSTIN, TX / ACCESSWIRE / October 29, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that it has been named Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook.

Monogram Technologies mBôs TKA Precision Robotic Surgical System
Monogram Technologies mBôs TKA Precision Robotic Surgical System

This award is in recognition of Monogram's stellar reputation and trust among customers and industry peers, evident in the numerous nominations received from Medical Tech Outlook's subscribers. Monogram emerged as an Orthopedic Joint Replacement Company of the Year 2024 after an exhaustive evaluation by an expert panel of C-level executives, industry thought leaders, and the editorial board.

"We are honored to be named Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook," said Ben Sexson, CEO of Monogram Technologies. "I would like to thank Medical Tech Outlook for this recognition and our incredible team for their hard work and dedication to our mission to advance the standard of care in orthopedic medicine. This award further validates Monogram's confidence in our mBôs TKA System, in the potential advantages of our technology, and our focus on improving human health. We look forward to updating investors and the market as we execute on our upcoming milestones."

For more information about Monogram Technologies, please visit ir.monogramorthopedics.com.

About Monogram Technologies Inc.

Monogram Technologies (NASDAQ: MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics.

Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored.

Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances.

The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation.

To learn more, visit monogramtechnologies.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. For example, the Company's statement regarding the Company's proposed use of net proceeds is a forward-looking statement. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Investor Relations

Contact Information

Chris Tyson
Executive Vice President
949-491-8235
MGRM@mzgroup.us

SOURCE: Monogram Technologies Inc.



View the original press release on accesswire.com

FAQ

Why did Monogram Technologies (MGRM) win the Orthopedic Joint Replacement Company of the Year 2024 award?

Monogram Technologies won the award due to their stellar reputation and trust among customers and industry peers, particularly for their mBôs TKA Precision Robotic Surgical System, following nominations from Medical Tech Outlook subscribers and evaluation by industry experts.

What is Monogram Technologies' (MGRM) main product in orthopedic surgery?

Monogram Technologies' main product is the mBôs TKA Precision Robotic Surgical System, which focuses on orthopedic joint replacement surgery.

Monogram Technologies Inc.

NASDAQ:MGRM

MGRM Rankings

MGRM Latest News

MGRM Stock Data

69.27M
22.57M
34.22%
3.85%
0.81%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
BROOKLYN